Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gossamer Bio Inc (NQ: GOSS )

0.7443 +0.0368 (+5.20%)
Streaming Delayed Price Updated: 3:39 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio Inc

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
Via Benzinga
Recap: Gossamer Bio Q3 Earnings
Via Benzinga
Analyst Expectations for Gossamer Bio's Future
Via Benzinga
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Although extremely small enterprises can be terrifyingly risky, these micro-cap stock surprises deserve a closer look. 
Via InvestorPlace
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Analyst Ratings for Gossamer Bio
Via Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Gossamer Bio And 2 Other Stocks Under $1 Insiders Are Buying
The Dow Jones closed higher by around 490 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Gossamer Bio Announces $212 Million Private Placement Financing
From Gossamer Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.